DNA extraction from placental, fetal and neonatal tissue at autopsy: what organ to sample for DNA in the genomic era?


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 18 06 2019
revised: 31 08 2019
accepted: 09 09 2019
pubmed: 23 10 2019
medline: 15 5 2020
entrez: 23 10 2019
Statut: ppublish

Résumé

Incorporation of genome and exome sequencing into fetal and neonatal autopsy investigations has been shown to improve diagnostic yield. This requires deoxyribonucleic acid (DNA) to be extracted from either the placenta or autopsy tissue for molecular testing. However, the sources and quality of DNA obtained are highly variable and there are no adequate published data on what tissue is most ideal to sample for DNA extraction in this setting. Here we compare the quality of DNA extracted from sampling the placenta and various solid organs at fetal and neonatal autopsy, thereby determining the optimal tissue from which to source DNA for ancillary testing as part of the modern perinatal autopsy. A total of 898 tissue samples were obtained at autopsy from 176 fetuses (gestational ages 17-40 weeks) and 44 neonates (age range 0-28 days) at our tertiary institution. Fetal tissue was processed using the QIAsymphony DSP DNA Mini kit and placental tissue was extracted using the New iGENatal Kit. DNA concentration was quantified using the Qubit dsDNA BR Assay Kit. DNA integrity, as stratified by gel electrophoresis was classified as high (≥5 kb) or low quality (<5 kb). Genome sequencing was performed on the extracted DNA, together with respective parental DNA from blood samples, and confirmed absence of maternal contamination in all cases. Analyses used logistic mixed models to test for associations between tissue types, intrauterine retention times, delivery to autopsy and death to autopsy intervals with DNA quality. In the fetal cohort, the placenta had the highest proportion of high quality DNA samples (93.1%), and liver had the lowest proportion (35.3%). Among the neonates, all tissue samples with the exception of liver had over 88% high DNA quality with the placenta also yielding the highest quality (100%). There was statistically significant deterioration in DNA quality with prolonged time interval between demise and autopsy (≥5 days). In the 726 fetal samples, the odds of obtaining higher quality DNA from the placenta, thymus, and spleen were 70.4 [95% confidence interval (CI) 29.2-169.6], 3.6 (95% CI 2.0-6.6) and 3.3 (95% CI 1.8-6.1) times, respectively, more likely than samples from the liver (p values <0.001). DNA yield from other fetal solid organs investigated was not significantly superior to that from the liver. This study shows that, when available, refrigerated unfixed placenta is the most suitable source of high quality DNA during perinatal investigations. Of the solid fetal organs sampled at autopsy, lymphocyte-rich, lytic enzymes-poor organs such as thymus and spleen were significantly more likely to yield good quality DNA than the liver.

Identifiants

pubmed: 31635948
pii: S0031-3025(19)30378-2
doi: 10.1016/j.pathol.2019.09.001
pii:
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

705-710

Informations de copyright

Copyright © 2019 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

Admire Matsika (A)

Anatomical Pathology, Mater Health, South Brisbane, Qld, Australia; Faculty of Medicine, University of Queensland, Qld, Australia. Electronic address: admire.matsika@mater.org.au.

Renee Gallagher (R)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Mark Williams (M)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Christopher Joy (C)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Emma Lowe (E)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Gareth Price (G)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Lachlan Webb (L)

QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.

Louise Marquart (L)

QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.

Anita Pelecanos (A)

QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.

James Harraway (J)

Genetic Pathology, Mater Health, South Brisbane, Qld, Australia.

Deon J Venter (DJ)

Anatomical Pathology, Mater Health, South Brisbane, Qld, Australia.

Jane E Armes (JE)

Anatomical Pathology, Mater Health, South Brisbane, Qld, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH